K
Karen Snyder
Researcher at Merck & Co.
Publications - 15
Citations - 1957
Karen Snyder is an academic researcher from Merck & Co.. The author has contributed to research in topics: Sitagliptin & Pharmacodynamics. The author has an hindex of 12, co-authored 15 publications receiving 1845 citations.
Papers
More filters
Journal ArticleDOI
Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes
Gary A. Herman,Arthur J. Bergman,Catherine Stevens,Paul Kotey,Bingming Yi,Peng Zhao,Bruno Dietrich,George Golor,Andreas Schrodter,Bart Keymeulen,Kenneth C. Lasseter,Mark Kipnes,Karen Snyder,Deborah Hilliard,Michael Tanen,Caroline Cilissen,Marina De Smet,Inge De Lepeleire,Kristien Van Dyck,Amy Qiu Wang,Wei Zeng,Michael J. Davies,Wesley Tanaka,Jens J. Holst,Carolyn F. Deacon,Keith Gottesdiener,John A. Wagner +26 more
TL;DR: In patients with type 2 diabetes, near maximal glucose-lowering efficacy of sitagliptin after single oral doses was associated with inhibition of plasma DPP-4 activity of 80% or greater, corresponding to a plasma sitgliptin concentration of 100 nm or greater and an augmentation of active GLP-1 and GIP levels of 2-fold or higher after an OGTT.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
Gary A. Herman,Cathy Stevens,Kristien Van Dyck,Arthur J. Bergman,Bingming Yi,Marina De Smet,Karen Snyder,Deborah Hilliard,Michael Tanen,Wesley Tanaka,Amy Qiu Wang,Wei Zeng,D.G. Musson,Gregory A. Winchell,Michael J. Davies,Steven Ramael,Keith Gottesdiener,John A. Wagner +17 more
TL;DR: Sitagliptin is an orally active, potent, and selective inhibitor of dipeptidyl peptidase IV (DPP‐IV) currently in phase III development for the treatment of type 2 diabetes.
Journal ArticleDOI
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Arthur J. Bergman,Catherine Stevens,YanYan Zhou,Bingming Yi,Martine Laethem,Marina De Smet,Karen Snyder,Deborah Hilliard,Wesley Tanaka,Wei Zeng,Michael Tanen,Amy Qiu Wang,Li Chen,Gregory A. Winchell,Michael J. Davies,Steven Ramael,John A. Wagner,Gary A. Herman +17 more
TL;DR: Assessment of the pharmacokinetic and pharmacodynamic properties and tolerability of multiple oral once-daily or twice-daily doses of sitagliptin found a finding consistent with near-maximal acute glucose lowering in preclinical studies.
Journal ArticleDOI
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Gary A. Herman,Arthur J. Bergman,Fang Liu,Cathy Stevens,Amy Qiu Wang,Wei Zeng,Li Chen,Karen Snyder,Deborah Hilliard,Michael Tanen,Wesley Tanaka,Alan G. Meehan,Kenneth C. Lasseter,Stacy C. Dilzer,Robert A. Blum,John A. Wagner +15 more
TL;DR: In nondiabetic obese subjects, treatment with sitagliptin 200 mg bid was generally well tolerated without associated hypoglycemia and led to maximal inhibition of plasma DPP‐4 activity, increased active GLP‐1, and reduced glycemic excursion.
Journal ArticleDOI
Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults
Ira Gantz,Ngozi Erondu,Madhuja Mallick,Bret J. Musser,Rajesh Krishna,Wesley Tanaka,Karen Snyder,Cathy Stevens,Mark Stroh,Haiyuan Zhu,John A. Wagner,Douglas J. MacNeil,Steven B. Heymsfield,John M. Amatruda +13 more
TL;DR: Intranasal PYY(3-36) as administered at these intervention doses and preprandial timing is not efficacious in inducing weight loss in obese patients after 12 wk of treatment.